ASH 2019 | From bb2121 to bb21217: does bb007 improve efficacy in MM?

Noopur Raje

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the CRB-402 study (NCT03274219) of bb21217, a next-generation anti-BCMA CAR T-cell therapy based on idecabtagene vicleucel (bb2121), that uses the same lentiviral CAR-T design, but adds the P3K inhibitor bb007 during ex vivo culture to enrich the drug product for memory-like T-cells, in order to increase persistence. Initial efficacy results with bb21217 CAR-T therapy in heavily pretreated relapsed/refractory multiple myeloma (MM) are encouraging. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter